Volitionrx (VNRX) Income from Non-Controlling Interests (2020 - 2025)
Volitionrx (VNRX) posted Income from Non-Controlling Interests of -$52868.0 for Q1 2025, up 17.2% on a QoQ basis from -$63854.0 in Q4 2024, and up 49.47% year-over-year from -$35371.4 in Q1 2024.
Volitionrx (VNRX) Income from Non-Controlling Interests (2020 - 2025) Analysis & Trends
Volitionrx's Income from Non-Controlling Interests history runs 5 years deep, the most recent figure standing at -$52868.0 for Q1 2025.
- Quarterly Income from Non-Controlling Interests rose 49.47% year-over-year to -$52868.0 in Q1 2025, while the trailing twelve-month figure through Mar 2025 was -$89142.0 (up 57.28% YoY) and the FY2024 annual result came in at -$290149.0, up 18.95% from the prior year.
- Income from Non-Controlling Interests was -$52868.0 for Q1 2025 at Volitionrx, up from -$63854.0 in the prior quarter.
- Across five years, Income from Non-Controlling Interests topped out at $94092.0 in Q4 2022 and bottomed at -$104617.0 in Q1 2024.
- A 4-year average of -$3285.8 and a median of -$47049.0 in 2024 frame the typical range for Income from Non-Controlling Interests.
- Peak annual rise in Income from Non-Controlling Interests reached 211.17% in 2023, while the deepest fall reached 219.6% in 2023.
- Volitionrx's Income from Non-Controlling Interests stood at $94092.0 in 2022, then tumbled by 207.82% to -$101450.0 in 2023, then soared by 37.06% to -$63854.0 in 2024, then climbed by 17.2% to -$52868.0 in 2025.
- Business Quant data shows VNRX's Income from Non-Controlling Interests at -$52868.0 in Q1 2025, -$63854.0 in Q4 2024, and -$47049.0 in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.32 Bn | 175.02 Bn | 6.27 Bn | - |
| 2 | Stryker | 128.75 Bn | 125.88 Bn | 3.81 Bn | - |
| 3 | Medtronic | 107.83 Bn | 98.61 Bn | 6.41 Bn | 16.00 Mn |
| 4 | Boston Scientific | 67.61 Bn | 66.15 Bn | 3.61 Bn | -2.00 Mn |
| 5 | Edwards Lifesciences | 48.13 Bn | 44.45 Bn | 1.29 Bn | - |
| 6 | Dexcom | 28.26 Bn | 27.14 Bn | 750.30 Mn | - |
| 7 | GE HealthCare Technologies | 27.78 Bn | 25.50 Bn | 1.98 Bn | 22.00 Mn |
| 8 | Smith & Nephew | 26.99 Bn | 26.41 Bn | - | - |
| 9 | Koninklijke Philips | 23.92 Bn | 20.80 Bn | 2.07 Bn | -5.85 Mn |
| 10 | Volitionrx | 89,525.10 | -1.03 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | -52,868.00 |
| Dec 31, 2024 | -63,854.00 |
| Sep 30, 2024 | -47,049.00 |
| Jun 30, 2024 | 74,629.00 |
| Mar 31, 2024 | -104,617.00 |
| Dec 31, 2023 | -101,450.00 |
| Sep 30, 2023 | -82,887.00 |
| Jun 30, 2023 | 80,298.00 |
| Mar 31, 2023 | 93,361.00 |
| Dec 31, 2022 | 94,092.00 |
| Sep 30, 2022 | 69,305.00 |
| Jun 30, 2022 | 82,302.00 |
| Mar 31, 2022 | -83,977.00 |
| Sep 30, 2020 | 8,050.00 |
| Jun 30, 2020 | 5,779.00 |
| Mar 31, 2020 | 9,567.00 |